NIAHA Advance Metabolic Slim™

The next generation of metabolic peptide innovation.

NIAHA Advance Metabolic Slim™ contains Retatrutide is an investigational triple hormone receptor agonist designed to support weight management and metabolic health by activating three naturally occurring hormone pathways: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.

This unique three-pronged approach has made Retatrutide one of the most promising investigational therapies currently being studied for obesity and related metabolic conditions.

Potential Benefits Observed in Clinical Research

Clinical studies have investigated retatrutide for its potential to:

● Support significant weight reduction when combined with healthy lifestyle changes.

● Reduce appetite and food cravings.

● Increase feelings of fullness (satiety).

● Improve blood glucose regulation.

● Enhance insulin sensitivity.

● Promote favourable changes in body composition during weight loss.

● Reduce waist circumference.

● Improve blood pressure and several markers of cardiometabolic health.

● Support improvements in metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease.

● Increase energy expenditure through its unique glucagon receptor activity, distinguishing it from GLP-1-only therapies. (BMJ⁠)

How Does Retatrutide Work?

Retatrutide is the first investigational therapy to simultaneously target three hormone receptors involved in metabolism:

● GLP-1 – helps reduce appetite, slows stomach emptying and supports healthy blood sugar regulation.

● GIP – enhances insulin response and contributes to appetite regulation.

● Glucagon – helps increase energy expenditure and influences fat metabolism.

By targeting all three pathways, researchers believe Retatrutide may offer broader metabolic benefits than therapies acting on one or two receptors alone.

Researchers continue to investigate Retatrutide for its potential role in:

● Obesity and long-term weight management

● Type 2 diabetes

● Prediabetes

● Metabolic syndrome

● Metabolic dysfunction-associated steatotic liver disease (MASLD)

● Cardiovascular and kidney health

● Obstructive sleep apnoea associated with obesity

● Knee osteoarthritis associated with excess body weight (Lilly⁠)